Granules India Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Smallcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Granules India reported strong full-year results with consolidated revenue growing 19.7% to Rs 53,656 million and profit rising 18.6% to Rs 5,950 million. Standalone revenue was Rs 30,302 million with profit of Rs 401 million, up 25.5% year-on-year. The company completed acquisition of Senn Chemicals AG (Switzerland) in April 2025 and Granules Pharmaceuticals GmbH (Germany) in November 2025, expanding its global footprint. The Gagillapur facility received a USFDA warning letter in February 2025 following an inspection, leading to temporary production pause and increased consultancy expenses. The Board recommended a dividend of Rs 1.75 per share. Auditors issued an unmodified opinion with no going concern issues.
Revenue growth nearly hit 20% on consolidated basis, with PAT growth exceeding 25% on standalone basis, indicating strong operational performance. The expansion into European markets through acquisitions should support future growth, though investors should monitor the resolution of USFDA concerns at Gagillapur facility.